Nature Communications (Mar 2021)
Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer
- Sylvan C. Baca,
- David Y. Takeda,
- Ji-Heui Seo,
- Justin Hwang,
- Sheng Yu Ku,
- Rand Arafeh,
- Taylor Arnoff,
- Supreet Agarwal,
- Connor Bell,
- Edward O’Connor,
- Xintao Qiu,
- Sarah Abou Alaiwi,
- Rosario I. Corona,
- Marcos A. S. Fonseca,
- Claudia Giambartolomei,
- Paloma Cejas,
- Klothilda Lim,
- Monica He,
- Anjali Sheahan,
- Amin Nassar,
- Jacob E. Berchuck,
- Lisha Brown,
- Holly M. Nguyen,
- Ilsa M. Coleman,
- Arja Kaipainen,
- Navonil De Sarkar,
- Peter S. Nelson,
- Colm Morrissey,
- Keegan Korthauer,
- Mark M. Pomerantz,
- Leigh Ellis,
- Bogdan Pasaniuc,
- Kate Lawrenson,
- Kathleen Kelly,
- Amina Zoubeidi,
- William C. Hahn,
- Himisha Beltran,
- Henry W. Long,
- Myles Brown,
- Eva Corey,
- Matthew L. Freedman
Affiliations
- Sylvan C. Baca
- Department of Medical Oncology, Dana-Farber Cancer Institute
- David Y. Takeda
- Laboratory of Genitourinary Cancer Pathogenesis, Center for Cancer Research, National Cancer Institute, NIH
- Ji-Heui Seo
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Justin Hwang
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Sheng Yu Ku
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Rand Arafeh
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Taylor Arnoff
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Supreet Agarwal
- Laboratory of Genitourinary Cancer Pathogenesis, Center for Cancer Research, National Cancer Institute, NIH
- Connor Bell
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Edward O’Connor
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Xintao Qiu
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Sarah Abou Alaiwi
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Rosario I. Corona
- Department of Obstetrics and Gynecology and the Women’s Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center
- Marcos A. S. Fonseca
- Department of Obstetrics and Gynecology and the Women’s Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center
- Claudia Giambartolomei
- Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California Los Angeles
- Paloma Cejas
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Klothilda Lim
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Monica He
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Anjali Sheahan
- Department of Oncologic Pathology, Dana-Farber Cancer Institute
- Amin Nassar
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Jacob E. Berchuck
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Lisha Brown
- Department of Urology, University of Washington
- Holly M. Nguyen
- Department of Urology, University of Washington
- Ilsa M. Coleman
- Divisions of Human Biology and Clinical Research, Fred Hutchinson Cancer Research Center
- Arja Kaipainen
- Divisions of Human Biology and Clinical Research, Fred Hutchinson Cancer Research Center
- Navonil De Sarkar
- Divisions of Human Biology and Clinical Research, Fred Hutchinson Cancer Research Center
- Peter S. Nelson
- Divisions of Human Biology and Clinical Research, Fred Hutchinson Cancer Research Center
- Colm Morrissey
- Department of Urology, University of Washington
- Keegan Korthauer
- Department of Data Sciences, Dana-Farber Cancer Institute
- Mark M. Pomerantz
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Leigh Ellis
- Department of Oncologic Pathology, Dana-Farber Cancer Institute
- Bogdan Pasaniuc
- Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California Los Angeles
- Kate Lawrenson
- Department of Obstetrics and Gynecology and the Women’s Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center
- Kathleen Kelly
- Laboratory of Genitourinary Cancer Pathogenesis, Center for Cancer Research, National Cancer Institute, NIH
- Amina Zoubeidi
- Vancouver Prostate Centre
- William C. Hahn
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Himisha Beltran
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Henry W. Long
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Myles Brown
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Eva Corey
- Department of Urology, University of Washington
- Matthew L. Freedman
- Department of Medical Oncology, Dana-Farber Cancer Institute
- DOI
- https://doi.org/10.1038/s41467-021-22139-7
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 12
Abstract
The molecular processes that lead to neuroendocrine prostate cancer after treating prostate adenocarcinoma (PRAD) are not well understood. Here the authors show that regulation by FOXA1 and changes in the epigenomic profile drive the transition from PRAD to a neuroendocrine phenotype.
